Pharmacoeconomics

Article	Citations
Economic Evaluation of Interventions to Reduce Antimicrobial Resistance: A Systematic Literature Review of Methods	516
The Societal Cost of Schizophrenia: An Updated Systematic Review of Cost-of-Illness Studies	192
Introduction to the Special Issue of PharmacoEconomics on Major Depressive Disorders	82
Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT)	78
The Burden of Type 2 Diabetes on the Productivity and Economy in Sub-Saharan Africa: A Life Table Modelling Analysis from a South African Perspective	75
Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children	70
A Comparison of the Psychometric Properties of the EQ-5D-Y-3L and EQ-5D-Y-5L Using Paediatric Multi-Instrument Comparison (P-MIC) Study Data	58
A Model-Based Economic Evaluation of Hypothetical Treatments for Amyotrophic Lateral Sclerosis in the UK: Implications for Pricing of New and Emerging Health Technologies	50
Examining the Effect of Depicting a Patient Affected by a Negative Reimbursement Decision in Healthcare on Public Disagreement with the Decision	45
The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment	41
Cost-Effectiveness of Plasma Microbial Cell-Free DNA Sequencing When Added to Usual Care Diagnostic Testing for Immunocompromised Host Pneumonia	38
Preference Elicitation Techniques Used in Valuing Children’s Health-Related Quality-of-Life: A Systematic Review	35
Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer	35
A Practical Guide to Modeling and Conducting a Cost-Effectiveness Analysis of Companion Biomarker Tests for Targeted Therapies Using R: Tutorial Paper	34
Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values	33
Estimating the Potential Benefits of Confirmatory Trials for Drugs with Accelerated Approval: A Comprehensive Value of Information Framework	31
The Validity of the EuroQol Health and Wellbeing Short Version (EQ-HWB-S) Instrument in Parents of Children With and Without Health Conditions	30
Estimating the Treatment and Prophylactic Economic Value of New Antimicrobials in Managing Antibiotic Resistance and Serious Infections for Common Pathogens in the USA: A Population Modelling Study	30
Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective?	25
Content Comparison of Quality-of-Life Instruments Used in Economic Evaluations of Sleep Disorder Interventions: A Systematic Review	25
Correction: Comparing the Psychometric Performance of Generic Paediatric Health‑Related Quality of Life Instruments in Children and Adolescents with ADHD, Anxiety and/or Depression	25
Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature	25
Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review	25
Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Mo	24
A Reporting Checklist for Discrete Choice Experiments in Health: The DIRECT Checklist	24

Unravelling Elements of Value of Healthcare and Assessing their Importance Using Evidence from Two Discrete-Choice Experiments in England	23
Public Health Impact of Introducing a Pentavalent Vaccine Against Invasive Meningococcal Disease in the United States	22
Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling	22
Considerations Around the Inclusion of Children and Young People’s Time in Economic Evaluation: Findings from an International Delphi Study	22
Collaborating with Patient Partners to Model Clinical Care Pathways in Major Depressive Disorder: The Benefits of Mixing Evidence and Lived Experience	21
A Comparison of Methods for Identifying Informal Carers: Self-Declaration Versus a Time Diary	21
Authors’ Reply to Comment on “Risk-Adjusted Performance Measures”	21
Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal	21
Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches	21
The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis	21
Correction to: Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)	20
Correction to: Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment	20
Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA	20
Considerations Around Coding the Membership Probability Function in a Latent Class Analysis: Renewed Insights	20
Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer’s Perspective	18
A Value Set for the EQ-5D-Y-3L in the Netherlands	18
Current Practices for Accounting for Preference Heterogeneity in Health-Related Discrete Choice Experiments: A Systematic Review	18
Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?	17
Getting the Price Right: Lessons for Medicare Price Negotiation from Peer Countries	17
Authors’ Response to “Preoperative Intravenous Iron for Iron Deficiency is Cost-Effective Prior to Major Elective Surgery”	16
Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model	16
Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment	16
How Much Better is Faster? Value Adjustments for Health-Improvement Sequences	16
Informal Caregiving Provision for Disabled or Elderly in the Families and Work Productivity: Evidence from 11 Waves of an Australian Population-Based Cohort	16
Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal	16
Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals	15
The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe	15
Using a Modified Delphi Approach to Gain Consensus on Relevant Comparators in a Cost-Effectiveness Model: Application to Prostate Cancer Screening	15
The Value of Genomic Testing: A Contingent Valuation Across Six Child- and Adult-Onset Genetic Conditions	14
Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments	14
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy	14
An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia	14
Correction: De Novo Cost‑Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation	14
Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease	13
Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers	13
Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment	13
Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force	13
Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review	12
Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective	12
Productivity Loss Across Socioeconomic Groups Among Patients With Low Back Pain or Osteoarthritis: Estimates Using the Friction-Cost Approach in Norway	12
An Evaluation of an Algorithm for the Selection of Flexible Survival Models for Cancer Immunotherapies: Pass or Fail?	12
The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers	12
Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy	12
Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting	11
Acknowledgement to Referees	11
Acknowledgement to Referees	11
Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review	11
The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review	11
Population Norms for the EQ-5D-5L, PROPr and SF-6D in Hungary	11
Overview and Use of Tools for Selecting Modelling Techniques in Health Economic Studies	11

Towards Recommendations for Cost-Effectiveness Analysis of Predictive, Prognostic, and Serial Biomarker Tests in Oncology	11
Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan	11
Systematic Review of Economic Evaluations of Systemic Treatments for Advanced and Metastatic Gastric Cancer	11
De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation	11
Acknowledgement to Referees	11
Advancing Methods to Measure and Reward Healthcare Innovation	11
Making Composite Time Trade-Off Sensitive for Worse-than-Dead Health States	10
Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)	10
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrin	10
How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment	10
Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review	10
Understanding Clinician Preferences for Treatment Attributes in Oncology: A Discrete Choice Experiment of Oncologists’ and Urologists’ Preferences for First-Line Treatment of Locally Advanced/Unresect	10
Identifying Attributes for a Value Assessment Framework in China: A Qualitative Study	10
Cost Effectiveness of Exclusionary EGFR Testing for Taiwanese Patients Newly Diagnosed with Advanced Lung Adenocarcinoma	10
Jointly Modelling Economics and Epidemiology to Support Public Policy Decisions for the COVID-19 Response: A Review of UK Studies	10
Does the Structure Matter? An External Validation and Health Economic Results Comparison of Event Simulation Approaches in Severe Obesity	9
Correction to: Dramatic Innovations in the Treatment of Spinal Muscular Atrophy, But Many Unknowns Remain	9
Health Economic Evaluation Using Markov Models in R for Microsoft Excel Users: A Tutorial	9
Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy	9
The Egyptian EQ-5D-5L Extensive Pilot Study: Lessons Learned	9
Characterization of the Pharmaceutical Risk-Sharing Arrangement Process in Catalonia	9
Deterministic Sensitivity Analysis Under Ignorance	9
Risk-Adjusted Performance Measures: A Comment on Elbasha	9
Extensions of Health Economic Evaluations in R for Microsoft Excel Users: A Tutorial for Incorporating Heterogeneity and Conducting Value of Information Analyses	9
Incorporating Real Option Value in Valuing Innovation: A Way Forward	9
Universal Health Coverage of Opioid Agonist Treatment in Norway: An Equity-Adjusted Economic Evaluation	9
Best Practices: A Collection of Systematic Critical Reviews of Modeling Approaches in Specific Disease Areas	9
A Systematic Review of the Methodologies and Modelling Approaches Used to Generate International EQ-5D-5L Value Sets	9
The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS	9
Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based	9
EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions	9
Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling	9
Unravelling the Association Between Uncertainties in Model-based Economic Analysis and Funding Recommendations of Medicines in Australia	9
Capturing the Impact of Constraints on the Cost-Effectiveness of Cell and Gene Therapies: A Systematic Review	9
Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges	9
Correction to: Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review	8
Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal	8
Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective	8
Comment on: A Framework for the Fair Pricing of Medicines	8
Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations	8
Cost Effectiveness of Strategies to Manage Atrial Fibrillation in Middle- and High-Income Countries: A Systematic Review	8
Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies	8
Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group P	8
Economic Evaluations Comparing Deep Brain Stimulation to Best Medical Therapy for Movement Disorders: A Meta-Analysis	8
Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE	8
Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK and the USA	8
Surrogacy and the Valuation of ATMPs: Taking Our Place in the Evidence Generation/Assessment Continuum	8
A Systematic Review of Methodologies Used in Models of the Treatment of Diabetes Mellitus	8
Evaluating the Public Health and Health Economic Impacts of Baloxavir Marboxil and Oseltamivir for Influenza Pandemic Control in China: A Cost-Effectiveness Analysis Using a Linked Dynamic Transmissio	7
Bayesian Meta-Analysis of Health State Utility Values: A Tutorial with a Practical Application in Heart Failure	7
Health Economists on Involving Patients in Modeling: Potential Benefits, Harms, and Variables of Interest	7
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the Unit	7
Correction to: A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population	7
Economic Burden Associated with Pulmonary Arterial Hypertension in the United States	7
A Systematic Review of Methods and Practice for Integrating Maternal, Fetal, and Child Health Outcomes, and Family Spillover Effects into Cost-Utility Analyses	7
Bring Out Your Dead: A Review of the Cost Minimisation Approach in Health Technology Assessment Submissions to the Australian Pharmaceutical Benefits Advisory Committee	7
Aspects and Challenges of Resource Use Measurement in Health Economics: Towards a Comprehensive Measurement Framework	7
Developing the EQ-5D-5L Value Set for Uganda Using the ‘Lite’ Protocol	7
The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature	7
Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of Bias	7
Correction to: Understanding Clinician Preferences for Treatment Attributes in Oncology: A Discrete Choice Experiment of Oncologists’ and Urologists’ Preferences for First-Line Treatment of Locally Ad	7
Immediate Versus 5-Year Risk-Guided Initiation of Treatment for Primary Prevention of Cardiovascular Disease for Australians Aged 40 Years: A Health Economic Analysis	7
The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing–Remitting Multiple Sclerosis	7
Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland	7
Economic Evaluations of Non-Pharmacological Interventions for Treating Disorders of Gut-Brain Interaction: A Scoping Review	7
Defining Biological and Clinical Plausibility: The DICSA Framework for Protocolized Assessment in Survival Extrapolations Across Therapeutic Areas	6
The EQ-5D-5L Valuation Study in Egypt	6
Economic Evaluation of Digital Health Interventions: Methodological Issues and Recommendations for Practice	6
Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid	6
Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens	6
Barriers and Facilitators of Using R for Decision Analytic Modeling in Health Technology Assessment: Focus Group Results	6
Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study	6
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel	6
Projecting the Health and Economic Burden of Cardiovascular Disease Among People with Type 2 Diabetes, 2022–2031	6
Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results from a UK Population Study	6
A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population	6
The Difference Method Approach for Sampling Order Constrained Parameters: An Improved Implementation and Important Limitations	6
Handling Missing Data in Health Economics and Outcomes Research (HEOR): A Systematic Review and Practical Recommendations	6
Cost-Effectiveness Analysis of MammaPrint® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer	6
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations	6

Costs and Cost-Effectiveness of Biomedical, Non-Surgical HIV Prevention Interventions: A Systematic Literature Review	6
PharmacoEconomics	6
Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective	6
Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease: An Updated Methodological Review	6
Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study	5
Measuring Effectiveness Based on Patient Experience (Instead of QALYs) in US Value Assessments	5
Evaluating the Quantity and Quality of Health Economic Literature in Blinding Childhood Disorders: A Systematic Literature Review	5
An Investigation of Inter-Rater and Intra-Proxy Agreement in Measuring Quality of Life of Children in the Community Using the EQ-5D-Y-3L	5
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management	5
Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses	5
Different Models, Same Results: Considerations When Choosing Between Approaches to Model Cost Effectiveness of Chimeric-Antigen Receptor T-Cell Therapy Versus Standard of Care	5
Time to Close the Gap Between Guidelines and the Reimbursement Policy for Diabetes Treatment in Turkey	5
An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada	5
A Blueprint for Multi-use Disease Modeling in Health Economics: Results from Two Expert-Panel Consultations	5
MPES-R: Multi-Parameter Evidence Synthesis in R for Survival Extrapolation—A Tutorial	5
A Systematic Review of Methods for Estimating Productivity Losses due to Illness or Caregiving in Low- and Middle-Income Countries	5
Mixture and Non-mixture Cure Models for Health Technology Assessment: What You Need to Know	5
Incorporating Complexity and System Dynamics into Economic Modelling for Mental Health Policy and Planning	5
Cost-Effectiveness Analysis of Pharmacogenomics (PGx)-Based Warfarin, Apixaban, and Rivaroxaban Versus Standard Warfarin for the Management of Atrial Fibrillation in Ontario, Canada	5
The RETRIEVE Checklist for Studies Reporting the Elicitation of Stated Preferences for Child Health-Related Quality of Life	5
Market Transparency in Medicine Pricing: Pathways to Fair Pricing	5
Delaying Oral Anticoagulants: A False Economy?	5
A Comparison of PROPr and EQ-5D-5L Value Sets	4
Rapid Assessment of the Need for Evidence: Applying the Principles of Value of Information to Research Prioritisation	4
Correction to: Contextual Considerations and Recommendations for Estimating the Value of Alzheimer’s Disease Therapies	4
Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal	4
The Opportunity of Point-of-Care Diagnostics in General Practice: Modelling the Effects on Antimicrobial Resistance	4
Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer	4
Conceptual Framework for Optimised Proxy Value Set Selection Through Supra-National Value Set Development for the EQ-5D Instruments	4
A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process	4
Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2− Advanced Breast Cancer: A Canadian Healthcare Perspective	4
Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review	4
Correction to: Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures	4
A Framework for Integrating Continuous Glucose Monitor-Derived Metrics into Economic Evaluations in Type 1 Diabetes	4
Mapping the Patient-Reported Outcomes Measurement Information System (PROMIS-29) to EQ-5D-5L	4
Value Set for the EQ-5D-Y-3L in Hungary	4
Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom	4
Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Gro	4
Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over Time	4
Lifetime Costs for Treated Follicular Lymphoma Patients in the US	4
Future Offspring Costs in Economic Evaluation	4
Preoperative Intravenous Iron for Iron Deficiency is Cost-Effective Prior to Major Elective Surgery	4
In a Child’s Shoes: Composite Time Trade-Off Valuations for EQ-5D-Y-3L with Different Proxy Perspectives	4
Economic Evaluations of Treatments for Duchenne Muscular Dystrophy: The Caregiver QALY Trap	3
Cost Effectiveness of Screening for Hepatitis C Virus in Iraq in the Era of Simplified Testing and Treatment	3
Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age Groups	3
The Use of Real-World Data for Estimating Relative Treatment Effects in NICE Health Technology Assessment Submissions: A Review	3
Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations	3
Economic Burden of Idiopathic Pulmonary Fibrosis in Spain: A Prospective Real-World Data Study (OASIS Study)	3
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK	3
Analytical Considerations When Anchoring Discrete Choice Experiment Values Using Composite Time Trade-Off Data: The Case of EQ-5D-Y-3L	3
Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial	3
Innovative Payment Models for Sickle-Cell Disease Gene Therapies in Medicaid: Leveraging Real-World Data and Insights from CMMI’s Gene Therapy Access Model	3
Exploring the Use of Pictorial Approaches in the Development of Paediatric Patient-Reported Outcome Instruments: A Systematic Review	3
Are We Agreed? Self- Versus Proxy-Reporting of Paediatric Health-Related Quality of Life (HRQoL) Using Generic Preference-Based Measures: A Systematic Review and Meta-Analysis	3
Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia	3
Calibrating Natural History of Cancer Models in the Presence of Data Incompatibility: Problems and Solutions	3
Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meni	3
Health-Related Quality-of-Life Outcomes of Very Preterm or Very Low Birth Weight Adults: Evidence From an Individual Participant Data Meta-Analysis	3
Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal	3
Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review	3
The Utility of a Rapid Review Evaluation Process to a National HTA Agency	3
Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment	3
Patient and Caregiver Treatment Preferences in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy: A Discrete Choice Experiment Survey in Five European Countries	3
Examination of Methods to Estimate Productivity Losses in an Economic Evaluation: Using Foodborne Illness as a Case Study	3
What are the Economic Costs to Society Attributable to Alcohol Use? A Systematic Review and Modelling Study	3
HTA Barriers for Conditional Approval Drugs	3
The Cost of Uncontrolled Blood Pressure in Australian General Practice: A Modelling Study Using Electronic Health Records (MedicineInsight)	3
Informal Care Costs According to Age and Proximity to Death to Support Cost-Effectiveness Analyses	3
Correction to: Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease	3
An EQ-5D-Y-3L Value Set for Belgium	3
Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal	2
Valuing SF-6Dv2 in Australia Using an International Protocol	2
State of the ART? Two New Tools for Risk Communication in Health Technology Assessments	2
Investigating the Association Between Self-Reported Comorbid Anxiety and Depression and Health Service Use in Cancer Survivors	2
Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers	2
Utility Values Associated with Atypical Hemolytic Uremic Syndrome-Related Attributes: A Discrete Choice Experiment in Five Countries	2
Importance of Patient Involvement in the Value Assessment Process: On the Way Towards Personalised Treatments	2
Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition	2
Drug Pricing Stewardship from Mark Cuban’s Cost Plus Generic Drug Program	2
Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective”	2
Do Costs in the Education Sector Matter? A Systematic Literature Review of the Economic Impact of Psychosocial Problems on the Education Sector	2
Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for Transparency	2
Response to Comment on Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening	2
Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA	2
A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects	2
Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence Models	2
Exploring the Issues of Valuing Child and Adolescent Health States Using a Mixed Sample of Adolescents and Adults	2
Value of Information for Clinical Trial Design: The Importance of Considering All Relevant Comparators	2
Integrating the Biology of Cardiovascular Disease into the Epidemiology of Economic Decision Modelling via Mendelian Randomisation	2
Improving Transparency of Decision Models Through the Application of Decision Analytic Models with Omitted Objects Displayed (DAMWOOD)	2
Why the Gap in Evaluating the Social Constructs and the Value of Medicines?	2
A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome	2
Using Age-Specific Values for Pediatric HRQoL in Cost-Effectiveness Analysis: Is There a Problem to Be Solved? If So, How?	2
How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents	2